Research
Trials
PEGASUS TIMI 54: Prevention
of Cardiovascular Events (eg, Death From Heart or Vascular Disease,
Heart Attack, or Stroke) in Patients With Prior Heart Attack Using
Ticagrelor Compared to Placebo on a Background of Aspirin - This
study is being carried out to see if a new drug called ticagrelor given
twice daily in addition to the ASA therapy decreases the frequency of
cardiovascular events (e.g., death from heart disease, heart attack, or
stroke).
IMPACT: The IMPACT of BIOTRONIK Home Monitoring Guided Anticoagulation on Stroke Risk in Patients With Implanted ICD and CRT-D Devices
- The IMPACT Study will investigate the clinical benefit of the
combined use of BIOTRONIK Home Monitoring (HM) technology and a
predefined anticoagulation plan compared to conventional device
evaluation and physician-directed anticoagulation in patients with
implanted dual-chamber defibrillators or cardiac resynchronization
therapy devices.
ATTAIN SUCCESS TRIAL
- The purpose of the study is to assess lead implant success and
complication rate using the Medtronic Attain Family of left-heart leads
and delivery catheters.
TRANSLATE-ACS:
Treatment With Adenosine Diphosphate (ADP) Receptor Inhibitors:
Longitudinal Assessment of Treatment Patterns and Events After Acute
Coronary Syndrome - a prospective, observational longitudinal
study to evaluate the real world effectiveness and use of prasugrel and
other ADP receptor inhibitor therapies among myocardial infarction (MI)
patients treated with percutaneous coronary intervention (PCI) during
the index hospitalization. Patient management and treatment decisions
are at the discretion of the care team per routine clinical practice.
The following are previous trials, which may be ongiong. Recruitment for new patients is closed:
CHAMPION: CardioMEMS Heart Sensor Allows
Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart
Failure Patients - This is a prospective, multi-center,
randomized, single-blind clinical
trial conducted in the United States (US). The objective of the study
is to evaluate the safety and efficacy of the HF Pressure Measurement
System in reducing heart failure (HF) related hospitalizations in a
subset of subjects suffering from HF.
SATURN: CRESTOR Athero Imaging Head to Head IVUS StudyA 104-week, randomized, double-blind, parallel group, multi-center
Phase IIIb study comparing the effects of treatment with rosuvastatin
40 mg or atorvastatin 80mg on atherosclerotic disease burden as
measured by intravascular ultrasound in patients with coronary artery
disease.
ZESCA:
- Patients who continue to smoke after a heart attack have a 35%
increased risk of a recurrent event or death compared with those who
quit. Many patients attempt to stop smoking after a heart attack, but
relapse rates approach 66%. A variety of smoking cessation aids have
been shown to be effective for the general population. However,
bupropion is the only non-nicotine replacement therapy shown to improve
abstinence rates in healthy young smokers. Furthermore, nicotine
replacement therapies (NRTs) are contraindicated in the immediate
period following a heart attack because of the undesirable effects of
nicotine. Although bupropion has been successfully used to reduce
smoking rates in healthy young populations, its efficacy and safety in
the setting of patients recovering from an ACS is unknown. These
patients, if they continue to smoke, are at exceptionally high risk for
recurrent cardiac events. If bupropion is effective in this population,
it will have a major impact on secondary prevention of recurrent
clinical events in patients who suffer a heart attack.
IMPROVE-IT:
Examining Outcomes in Subjects With Acute Coronary Syndrome:Vytorin
(Ezetimibe/Simvastatin) vs Simvastatin (Study P04103) -
This is a randomized, active-control, double-blind study of
subjects
with stabilized high-risk acute coronary syndrome (ACS). The primary
objective is to evaluate the clinical benefit of Ezetimibe/Simvastatin
Combination 10/40 (single tablet, under the brand VYTORIN in the United
States) compared with Simvastatin 40 mg. Clinical benefit will be
defined as the reduction in the risk of the occurrence of the composite
endpoint of CV death, major coronary events, and stroke.
A
Comparison of AZD6140 and Clopidogrel in Patients With Acute Coronary
Syndrome (PLATO) - AZD6140 is a
new, reversible, anti-platelet medication. Anti-platelet
medications work to prevent the formation of blood clots. AZD6140 is
being developed as a treatment for patients with acute coronary
syndrome (ACS). ACS is a term that is used to describe both heart
attacks in progress or the imminent threat of a heart attack. ACS is
usually caused by the formation of a blood clot in an artery that
partially or totally blocks the blood supply to a portion of the heart
muscle. AZD6140 will be compared with clopidogrel to determine which
drug, when either is used in conjunction with aspirin, is better at
reducing deaths from vascular causes, future heart attacks and/or
strokes in patients with ACS.
Randomized
Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate
- The primary objective of this trial is to demonstrate
the efficacy and
safety of dabigatran etexilate in patients with non-valvular atrial
fibrillation for the prevention of stroke and systemic embolism.
DAL-Outcomes)
- This study will evaluate the potential of RO4607381 to reduce
cardiovascular morbidity and mortality in stable coronary heart disease
patients with recent Acute Coronary Syndrome (ACS) and evaluate the
long term safety profile of the drug. Eligible patients in stable
condition will be randomized to receive either RO4607381 600mg po or
placebo po, daily, together with a background of standard medication
for ACS (including aspirin, antihypertensives and statins). The
anticipated time on study treatment is 2+ years, and the target sample
size is 500+ individuals.